当前位置: 首页 > 期刊 > 《中国当代医药》 > 2019年第17期
编号:13421790
奥卡西平联合氟哌噻吨美利曲辛片治疗原发性三叉神经痛患者的临床效果(1)
http://www.100md.com 2019年6月15日 《中国当代医药》 2019年第17期
     [摘要]目的 探讨奥卡西平联合氟哌噻吨美利曲辛片治疗原发性三叉神经痛(PTN)患者的临床效果。方法 选取2016年10月~2018年10月我院收治的68例PTN患者,按随机数字表法分为试验组(n=34)与对照组(n=34)。对照组予以奥卡西平治疗,试验组予以奥卡西平联合氟哌噻吨美利曲辛片治疗,两组均治疗3个月。比较两组的临床效果、不良反应发生率以及治疗前、治疗1、3个月后的视觉模拟评分量表(VAS)、匹兹堡睡眠质量指数(PSQI)评分。结果 治疗3个月后,试验组的总有效率为94.12%(32/34),高于对照组的73.53%(25/34)(P<0.05);两组治疗前的VAS、PSQI评分比较,差异无统计学意义(P>0.05);两组治疗1、3个月后的VAS、PSQI评分均较治疗前降低,且试验组低于对照组(P<0.05);试验组的不良反应总发生率为17.65%,与对照组的8.82%比较,差异无统计学意义(P>0.05)。结论 联合应用奥卡西平与氟哌噻吨美利曲辛片治疗原发性三叉神经痛患者可提高临床效果,减轻疼痛感,改善睡眠质量,且具有安全性。

    [關键词]原发性三叉神经痛;奥卡西平;氟哌噻吨美利曲辛片;疼痛程度;睡眠质量

    [中图分类号] R745.1+1 [文献标识码] A [文章编号] 1674-4721(2019)6(b)-0137-04

    [Abstract] Objective To explore the clinical effect of Oxcarbazepine combined with Flupentixol and Melitracen Tablets in the treatment of patients with primary trigeminal neuralgia (PTN). Methods A total of 68 PTN patients treated in our hospital from October 2016 to October 2018 were selected and divided into the study group (n=34) and the control group (n=34) according to random number table method. Patients in the control group were given Oxcarbazepine, and those in the study group were given Oxcarbazepine combined with Flupentixol and Melitracen Tablets. Both groups were treated for 3 months. The clinical effects, the incidence of adverse reactions, and the scores of visual analogne scale (VAS) and Pittsburgh sleep quality index scale (PSQI) before treatment and 1 month and 3 months after treatment were compared between the two groups. Results After 3 months of treatment, the overall effective rate of the study group was 94.12% (32/34), which was higher than 73.53% (25/34) of the control group (P<0.05). There was no significant difference in the VAS and PSQI scores between the two groups before treatment (P>0.05), and both scores were reduced in both groups at 1 and 3 months after treatment, and those in the study group were lower than those in the control group (P<0.05). The total incidence of adverse reactions in the study group was 17.65%, and there was no significant difference between the experimental group and the control group (8.82%) (P>0.05). Conclusion Oxcarbazepine combined with Flupentixol and Melitracen Tablets can improve the clinical effect in the treatment of patients with primary trigeminal neuralgia, relieve the pain of patients, improve the sleeping quality, and have high safety.

    [Key words] Primary trigeminal neuralgia; Oxcarbazepine; Flupentixol and Melitracen Tablets; Pain degree; Sleeping quality, 百拇医药(谌锐)
1 2 3下一页